incyclix

RESEARCH TRIANGLE PARK – Incyclix, an emerging biotech focusing on the fight against cancer, has secured nearly $3 million in a $30 million round announced in 2022. In an SEC filing, the company, whose founders include PPD Inc. founder and investor Fred Eshelman, says funding will be added incrementally...

Fourteen years ago, the founders of Incyclix Bio were part of a different team with a shared vision – seven words scrawled on a lab whiteboard at the University of North Carolina at Chapel Hill – “It’s a good day to cure cancer.” Now they have $30 million to keep searching for a cure.